(Q39600801)

13 September 2017

1 reference

title

The non-Hodgkin's lymphomas: pathology, staging, treatment (English)

1 reference

13 September 2017

Hoppe RT

1

1 reference

13 September 2017

language of work or name

1 reference

1 November 1987

1 reference

Current Problems in Cancer

13 September 2017

published in

1 reference

13 September 2017

volume

11

1 reference

13 September 2017

issue

6

1 reference

13 September 2017

page(s)

363-447

1 reference

Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Effect of the degree of nodularity on the survival of patients with nodular lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Clinical and pathologic features of follicular large cell (nodular histiocytic) lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Malignant lymphoma, diffuse mixed small and large cell. A clinicopathologic study of 47 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Clinical Relevance of the Histopathological Subclassification of Diffuse “Histiocytic” Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Subcategories of histiocytic lymphoma: associations with survival and reproducibility of classification. The Southeastern Cancer Study Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Morphologic types of diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Clinical course of retrovirus-associated adult T-cell lymphoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Malignant lymphoma of peripheral T-lymphocyte origin.Immunologic, pathologic, and clinical features in six patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Malignant lymphoma with a high content of epitheloid histiocytes (Lennert's lymphoma).

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Malignant lymphoma with a high content of epithelioid histiocytes.A distinct clinicopathologic entity and a form of so-called „Lennert's Lymphoma”

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Peripheral T-cell lymphoma. A clinicopathologic study of a morphologically diverse entity

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Undifferentiated non-Hodgkin's lymphomas (Burkitt's and non-Burkitt's types). The relevance of making this histologic distinction

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Histopathologic review of lymphoma cases from the southwest oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Classification of non-Hodgkin's lymphomas. Reproducibility of major classification systems. NCI non-Hodgkin's Classification Project Writing Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Predictability of immunologic phenotype by morphologic criteria in diffuse aggressive non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Adult non-Hodgkin's lymphoma. Correlation of cell surface marker phenotype with prognosis, the new working formulation, and the Rappaport and Lukes-Collins histomorphologic schemes

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Immunologic methods in cytology: definitive diagnosis of non-Hodgkin's lymphomas using immunologic markers for T- and B-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

T-cell receptor gene rearrangements as clinical markers of human T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Diagnosis of B cell lymphoma by analysis of immunoglobulin gene rearrangements in biopsy specimens obtained by fine needle aspiration

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Detection of B-cell lymphoma in peripheral blood by DNA hybridisation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Treatment of lymphoblastic lymphoma in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Role of radiation therapy in localized non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Spleen structure in Hodgkin disease: ultrasonic characterization. Work in progress

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Stage IV diffuse large-cell lymphoma: a long-term analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Radiographic distribution of intrathoracic disease in previously untreated patients with Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Hodgkin disease: contributions of chest CT in the initial staging evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Contribution of computed tomography to the treatment of lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

A retrospective evaluation of mediastinal tomograms, isotope liver scans, and isotope bone scans in the staging and management of patients with lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

High-dose gallium imaging in lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Sequential pathologic staging of untreated non-Hodgkin's lymphomas by laparoscopy and laparotomy combined with marrow biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Laparotomy findings in lymphangiogram-staged I and non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

EOE-13 in the detection of hepatosplenic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

The detection of bone marrow involvement by lymphoma using magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Non-Hodgkin's lymphoma.Involvement of Waldeyer's ring

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Abdominal irradiation in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Recurrence Rates Following Radiation Therapy of Nodular and Diffuse Malignant Lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Recovery of spermatogenesis following pelvic irradiation for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Pregnancy following oophoropexy and total nodal irradiation in women with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Female Reproductive Potential after Treatment for Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Non-Hodgkin's lymphomas. II. Single agent chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

High-dose pulse chlorambucil: effective therapy for rapid remission induction in nodular lymphocytic poorly differentiated lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Advanced Lymphosarcoma: Intensive Cyclical Combination Chemotherapy with Cyclophosphamide, Vincristine, and Prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Advanced diffuse histiocytic lymphoma, a potentially curable disease

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies, stages I and II

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Prognostic factors in non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Treatment of early--stages I and II--nodular, poorly differentiated lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Stage I-II follicular lymphoma. Treatment results for 76 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Follicular lymphoma: prognostic factors for response and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Stage III nodular lymphoreticular tumors (non-Hodgkin's lymphoma): Results of central lymphatic irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

The role of radiation therapy in the management of stage III follicular lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Multimodality therapy of favorable prognosis non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Prolonged Initial Remission in Patients with Nodular Mixed Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Histologic conversion in the non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Long-term survival of patients with localized diffuse histiocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Localised grade 2 non-Hodgkin's lymphoma: results of treatment with radiotherapy (BNLI Report No. 24).

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Extralymphatic involvement in diffuse non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Cutaneous malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Cutaneous malignant lymphoma: a pathologic study of 50 cases with clinical analysis of 37.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Non-Hodgkin's lymphoma presenting as thyroid enlargement

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Malignant lymphoma of the thyroid gland

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Radiotherapeutic management of primary thyroid lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Management of primary gastric lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Diffuse histiocytic lymphoma involving the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Diffuse histiocytic lymphoma presenting with gastrointestinal tract lesions. The Stanford experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Curability of gastrointestinal lymphoma with combined surgery and radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Stages IE and IIE non-Hodgkin's lymphomas of the stomach: Comparison of treatment modalities

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Non-Hodgkin's lymphoma of the stomach: a prospective pilot study of surgery plus chemotherapy in early and advanced disease

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Should lymphomas of gastrointestinal tract be treated differently from other disease presentations?

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Primary lymphoma of the central nervous system. Clinicopathological study of experience at Stanford

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Developments in the diagnosis and treatment of primary CNS lymphoma. A prospective series

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Non-Hodgkin's lymphomas of head and neck extranodal sites

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

1 reference

7 January 2021

Clinical aspects of non-Hodgkin's lymphomas presenting with discordant histologic subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Autologous bone marrow transplantation in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

The current status of monoclonal antibodies in the diagnosis and therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Prognostic signs and the management of the mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Mycosis fungoides: management with topical nitrogen mustard

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

Extracutaneous mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2887%2980006-5

7 January 2021

10.1016/S0147-0272(87)80006-5

Identifiers

DOI

1 reference

13 September 2017

1 reference